Galena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, August 9, 2016

SAN RAMON, Calif., July 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma GALE, a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that the Company will report its second quarter 2016 financial results and provide a corporate update on Tuesday, August 9, 2016 after the close of the financial markets.  The company will host a conference call following the announcement at 2:00 p.m. P.T./5:00 pm E.T. to discuss the financial and business results.

The live webcast will include slides that can be accessed on the Company's website under the Investors section/Events and Presentations: http://investors.galenabiopharma.com/events.cfm. The conference call can be accessed by dialing (844) 825-4413 toll-free in the U.S., or (973) 638-3403 for participants outside the U.S. The Conference ID number is: 51743330.  The archived webcast replay will be available on the Company's website for one year. 

About Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena's development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The company's pipeline consists of multiple mid-to-late-stage clinical assets, including novel cancer immunotherapy programs with NeuVax™ (nelipepimut-S) and GALE-301/GALE-302, and one hematology program, GALE-401. For more information, visit www.galenabiopharma.com.

NeuVax is a trademark of Galena Biopharma, Inc.